MX2018006790A - Composiciones que contienen decitabina, 5azacitidina y etrahidrouridina y sus usos. - Google Patents

Composiciones que contienen decitabina, 5azacitidina y etrahidrouridina y sus usos.

Info

Publication number
MX2018006790A
MX2018006790A MX2018006790A MX2018006790A MX2018006790A MX 2018006790 A MX2018006790 A MX 2018006790A MX 2018006790 A MX2018006790 A MX 2018006790A MX 2018006790 A MX2018006790 A MX 2018006790A MX 2018006790 A MX2018006790 A MX 2018006790A
Authority
MX
Mexico
Prior art keywords
tetrahydrouridine
compositions containing
decitabine
containing decitabine
compositions
Prior art date
Application number
MX2018006790A
Other languages
English (en)
Inventor
Saunthararajah Yogen
Vadivelu Santhosh
Desimone Joseph
Lau Henry
Original Assignee
Epidestiny Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidestiny Inc filed Critical Epidestiny Inc
Publication of MX2018006790A publication Critical patent/MX2018006790A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones que comprenden decitabina y tetrahidrouridina o 5-azacitidina y tetrahidrouridina para el tratamiento del cancer. Las composiciones en forma de pildora se administran a un sujeto humano en secuencia o de manera alternada en funcion de la medicion de biomarcadores predictivos.
MX2018006790A 2015-12-03 2016-12-05 Composiciones que contienen decitabina, 5azacitidina y etrahidrouridina y sus usos. MX2018006790A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262839P 2015-12-03 2015-12-03
US201662429292P 2016-12-02 2016-12-02
PCT/US2016/064935 WO2017096357A1 (en) 2015-12-03 2016-12-05 Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof

Publications (1)

Publication Number Publication Date
MX2018006790A true MX2018006790A (es) 2019-05-02

Family

ID=58798100

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021007569A MX2021007569A (es) 2015-12-03 2016-12-05 Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos.
MX2018006790A MX2018006790A (es) 2015-12-03 2016-12-05 Composiciones que contienen decitabina, 5azacitidina y etrahidrouridina y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021007569A MX2021007569A (es) 2015-12-03 2016-12-05 Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos.

Country Status (9)

Country Link
US (3) US11376270B2 (es)
EP (2) EP3383406B1 (es)
JP (2) JP7194021B2 (es)
CN (1) CN109789155A (es)
BR (1) BR112018011324A2 (es)
CA (1) CA3007357C (es)
DK (1) DK3383406T3 (es)
MX (2) MX2021007569A (es)
WO (1) WO2017096357A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220226355A1 (en) * 2019-05-24 2022-07-21 The Cleveland Clinic Foundation Timed alternate administration of decitabine and 5-azacytidine for cancer treatment
US20210077492A1 (en) * 2019-09-17 2021-03-18 The Trustees Of Indiana University Methods and compositions of treating pancreatic cancer
WO2021211890A1 (en) * 2020-04-16 2021-10-21 Adimabio Llc Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
CA3236051A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
ATE339960T1 (de) 1999-03-01 2006-10-15 Halogenetics Inc Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungen
US6861513B2 (en) 2000-01-12 2005-03-01 Schering Corporation Everninomicin biosynthetic genes
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20050056280A1 (en) 2002-12-31 2005-03-17 Nektar Therapeutics Receptacle for an aerosolizable pharmaceutical formulation
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
MX2008001709A (es) 2005-08-01 2008-11-26 Nupotential Inc Produccion de celulas reprogramadas con potencial restablecido.
MX2010003261A (es) 2007-09-26 2010-08-18 Sinai School Medicine Analogos de azacitidina y usos de los mismos.
EP2050757A1 (en) * 2007-10-10 2009-04-22 Cilag AG Method of producing 2' -deoxy-5-azacytidine (Decitabine)
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
LT3782612T (lt) 2008-05-15 2023-12-27 Celgene Corporation Geriamosios citidino analogų kompozicijos ir jų naudojimo būdai
US9265785B2 (en) * 2008-12-22 2016-02-23 The Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
US9259469B2 (en) 2008-12-22 2016-02-16 The Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
JP6063628B2 (ja) 2009-02-10 2017-01-18 セルジーン インターナショナル サルル ５−アザシチジンを用いる、非小細胞肺癌の治療方法
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
WO2010118010A1 (en) 2009-04-06 2010-10-14 Eisai Inc. Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
WO2010118013A1 (en) 2009-04-06 2010-10-14 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
CN102485232A (zh) * 2010-12-06 2012-06-06 苏州科耐尔医药科技有限公司 一种含地西他滨的药物组合物
MX2013006020A (es) * 2011-01-31 2013-10-01 Celgene Corp Composicion farmaceutica de analogos de citidina y metodos para su uso.
US8426143B2 (en) * 2011-05-24 2013-04-23 Saladax Biomedical Inc. Gemcitabine immunoassay
US9476099B2 (en) 2012-08-10 2016-10-25 Trustees Of Dartmouth College Method for determining sensitivity to decitabine treatment
US20140100182A1 (en) 2012-10-05 2014-04-10 The Cleveland Clinic Foundation Nanogel-Mediated Drug Delivery
WO2014143051A1 (en) 2013-03-15 2014-09-18 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer

Also Published As

Publication number Publication date
US20220152075A1 (en) 2022-05-19
JP2018538370A (ja) 2018-12-27
JP7194021B2 (ja) 2022-12-21
JP2022184941A (ja) 2022-12-13
MX2021007569A (es) 2022-06-09
WO2017096357A1 (en) 2017-06-08
CA3007357A1 (en) 2017-06-08
US11779591B2 (en) 2023-10-10
CN109789155A (zh) 2019-05-21
US20240165142A1 (en) 2024-05-23
EP3383406A4 (en) 2019-08-21
EP3960182A1 (en) 2022-03-02
EP3383406B1 (en) 2021-10-20
US11376270B2 (en) 2022-07-05
CA3007357C (en) 2023-12-05
BR112018011324A2 (pt) 2018-12-04
US20200246368A1 (en) 2020-08-06
EP3383406A1 (en) 2018-10-10
DK3383406T3 (da) 2022-01-10

Similar Documents

Publication Publication Date Title
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
ZA201907641B (en) Treatment of cancer by manipulation of commensal microflora
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2019012233A (es) Anticuerpos anti-sirpa.
MX2023008686A (es) Polinucleotidos moduladores.
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12017502086A1 (en) Cancer treatments
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
MX364486B (es) Derivados de piridazinona-amidas.
MX2021007569A (es) Composiciones que contienen decitabina, 5azacitidina y tetrahidrouridina y sus usos.
MX364814B (es) Nucleosidos biciclicos unidos en puente.
EA201791845A1 (ru) Твердые формы менахинолов
EP3341079A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
IN2013MU03118A (es)
UA108007C2 (en) Composition of marmalade with health-improving properties "tasty"
佐藤格 et al. Hyperthermia generated with ferucarbotran (Resovist®) in an alternating magnetic field enhances cisplatin-induced apoptosis of cultured human oral cancer cells
MX367975B (es) Ciclodipéptidos de origen bacteriano con propiedades anticancerígenas y sus usos en el tratamiento del cáncer.
GR20150200058U (el) Καλλυντικα με σπιρουλινα
MX357132B (es) Uso de la inulina para el tratamiento de manifestaciones clínicas asociadas con la cirrosis hepática.
AR087666A1 (es) Composicion acondicionadora del cabello
UA108006C2 (en) Composition of marmalade with health-improving properties "freshness"